CPH Chemie + Papier : 1H2022 Results update 26 July 2022 (pdf, 216kb)

This report has been issued for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of third parties regarding revenues, earnings and business developments. Such estimates and forecasts cannot be independently verified by reason of the subjective character. CPH Chemie + Papier Holding AG gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.

This report is not a prospectus within the meaning of art. 652a CO or art. 27 et seq. of the SIX Listing Rules. This document is neither an advice on investment, nor a recommendation or invitation for purchasing, holding or selling any securities, money market instruments or derivatives and no investment decision should be based on this report. This report speaks as of its date. Neither CPH Chemie + Papier Holding AG nor Dynamics Group AG assume any responsibility to up-date the report.

CPH Chemie + Papier Holding AG

Switzerland | Industrial Goods & Services

1H2022 Results update

26 July 2022

Company Data

Price:	CHF 73.00
Market Cap:	CHF 438.0mn
Free Float:	56.9%
No. of shares:	6.0mn
Avg. traded volume (30 day):	1,343
Bloomberg:	CPHN SW
Reuters:	CPHN-EB
ISIN:	CH0001624714

Source: SIX Swiss Exchange and Bloomberg

Share Price Development

120

110

100

90

80

Jun-21	Sep-21	Dec-21	Apr-22	Jul-22
		CPH	SPI
Source: Bloomberg
Key Financial Data
		2020	2021	2022E	2023E
Sales		445.2	496.7	707.4	645.3
EBITDA %		12.4%	5.2%	14.7%	11.9%
EBIT %		5.5%	(0.5%)	11.9%	8.6%
Net Margin %	10.5%	(30.5%)	10.8%	7.0%
Basic EPS		7.82	(25.26)	12.74	7.49
Diluted EPS		7.82	(25.26)	12.74	7.49
DPS		1.80	1.30	1.30	1.80
Equity Ratio %	66.8%	55.2%	58.1%	62.0%
Capex		(13.5)	(19.4)	(51.6)	(28.9)
P/Sales		0.9x	0.8x	0.6x	0.0x
P/E		8.6x	NM	5.7x	9.7x
EV/EBITDA		7.1x	15.3x	4.4x	5.9x
Source: Research Dynamics, Company data
Next Events
CMD				13 Sept 2022
ZKB Equity Conference		3/4 Nov 2022
FY 2022 report			21 Feb 2023

Analysts

Doris Rudischhauser [e-mail]

Alexandre Müller [e-mail]

Tel: [phone]

www.researchdynamics.ch

Broad-based growth across all divisions

Better volumes and realizations of price increases lift profitability

For 1H2022, CPH's net sales increased 47.7% YoY to CHF 360mn, driven by growth in all three segments thanks to strong demand, despite the adverse impacts of Ukraine war, COVID- 19 related lockdowns in China and challenges in raw material procurement. Adjusted for currency fluctuations, topline growth would have amounted to 51%. The Paper Division's revenue improved significany by 78% YoY, mainly due to lower paper production volumes as a result of permanent capacity closures and a long strike at one of the Paper division's competitiors. The Chemistry and the Packaging Divisions registered 18.9% YoY and 27.5% YoY growth, respectively. Despite the substantial rise in raw material prices, transport and energy costs, the company's EBITDA increased significantly to CHF 61.7mn (1H2021: CHF 20.0mn) and the corresponding margin expanded to 17.1% (1H2021: 8.2%). During the first half-year, the company's Paper and Packaging division reversed its margin decline of the prior- year period. Along with strong volumes, higher sales price and lower depreciation following the fixed asset impairment charges in FY2021, this enabled the company to record substantial growth in EBIT to CHF 51.9mn (1H2021: CHF 5.7mn) and the corresponding margin expanded to 14.4% (1H2021: 2.4%). The net result of the company attributable to common shareholders improved to CHF 47.5mn (1H2021: CHF 5.9mn).

Segmental performance

Paper: In 1H2022, net sales of the Paper division increased 78.0% YoY to CHF 187.6mn. During 1H2022, there was a slight increase in demand for newsprint, whereas the demand for magazine paper declined in Western Europe. The paper production was hampered due to permanent capacity closures and a long strike at one of the Paper Divisions' competitors. Also, another competitor announced the sale of four out of five of its paper factories. This led to higher paper prices and enabled the company to reverse its margin decline from the prior year period despite a significant increase in costs of energy and the division's prime raw materials like waste wood and recovered paper. As a result, the division's EBIT came in at CHF 34mn (1H2021: loss of CHF 10.1mn) and the corresponding margin at 18.1% (1H2021: -9.6%).

Packaging: Net sales were up 27.5% YoY to CHF 115.8mn (1H2021: CHF 90.8mn) driven by an increase in sales volume and prices along with a growing proportion of high-barrier films sold. Further, the demand for pharmaceutical packagings was high in Europe in 1H2022 mainly for non-prescription medicines. Also, pharmaceutical manufacturers added stocks of packaging films, anticipating a shortage in availabilities in the future. All of the division's production facilities were well utilised and witnessed high order volumes. Despite the coronavirus restrictions imposed by the Chinese government, production in Suzhou was not directly impacted. The company witnessed higher transportation and raw material costs in 1H2022. However, the higher costs were largely passed on to end users, enabling the company to record an EBIT of CHF 11.2mn (1H2021: CHF 8.4mn) and the corresponding margin expanded to 9.7% (1H2021: 9.3%).

Chemistry: Net sales increased 18.9% YoY to CHF 56.4mn, driven by improved demand in all product segments as facilities were operating at high capacity utilisations during 1H2022. The division is set to invest in additional capacities at its sites in the USA, China, Bosnia and Herzegovina, and Switzerland. However, as prices of raw materials increased at double-digit rates along with major challenges in the division's transport logistics (e.g delivery delays due to the closure of Shanghai port), the divison's EBIT fell 1.6% YoY to CHF 7.3mn and the corresponding margin contracted to 13% (1H2021: 15.7%).

Cautious outlook for FY2022

The near-termmacro-economic uncertainties like the impact of geopolitical unrest between Russia and Ukraine on energy supplies, supply chain disruptions and ramifications of interest rate hikes by central banks in response to rising inflation resulted in management having a cautious outlook for 2H2022.

Group: Concrete divisional developments will depend on the unfolding of macro-economic uncertainties in the key markets and time lags in passing on the higher raw material costs to the market. Management expects FY2022 sales to be substantially higher than in FY2021 and

Important disclosures are on the last page of this report. CPH Chemie + Papier Holding AG is a research client of Research Dynamics. The equity research reports are prepared for information purposes only.

CPH 2

Switzerland | Industrial Goods & Services

an EBIT high double-digit millions. In absence of any unforeseen circumstances, the net result is expected in a similar range.

Paper: Raw material prices are expected to remain at high levels in 2H2022 and further price rises can not be ruled out. This along with supply-demand balance is expected to determine the paper price trends. The Paper division expects to maintain its net sales growth, however, the operating margin could start to be under pressure in 2H2022.

Packaging: Despite the new coating plant in Brazil commencing its operations in autumn, the division's net sales are expected to slow down in 2H2022. Moreover, with plans to pass on the raw materials costs to the market, the operating margin in 2H2022 should be broadly maintained at the 1H2022 level.

Chemistry: Product demand is likely to improve leading to higher order volumes. With the lithium product manufacturing capacity in the USA coming into operation, the company expects to report double-digit net sales growth in FY2022. However, due to rising raw material and transport costs, margins are expected to be under pressure, slightly below the FY2021 levels.

Noteworthy Events:

Perlen Packaging and Cipatex collaborate on mono PVC pharmaceutical films: To expand its activities in Latin America, Perlen Packaging entered into an exclusive collaboration with Brazil-basedPVC manufacturer Cipatex on 05 July 2022. As a part of the collaboration, the Group will support the modernisation of Cipatex's facility at Sao Paulo to align it fully to pharmaceutical mono PVC film requirements. This collaboration is in line with the Group's strategy of maintaining its own coating capacities in the pharmaceutical sector's key areas in Europe, Asia and the Americas. Further, the collaboration should also ensure the long-termand reliable supply of high-qualitymono PVC films.

Valuation and conclusion

We value CPH using DCF and relative valuation techniques. Our intrinsic value of CHF 97.7 per share is higher than the previous target price (CHF 92.3) and implies an upside of ~34.0% from current levels. For relative valuation, since the Group operates in three entirely different divisions, we compare each of CPH's divisions with different sets of relevant industry peers. We have employed three parameters - EV/EBITDA, P/S, and P/E - to analyze the relative valuation of the Group. CPH currently trades at a EV/EBITDA multiple of 5.9x (FY2023E), a significant 27% discount to the weighted average multiple of division peers.

The global economy is expected to recover gradually, with the IMF slashing 2022e and 2023e forecast to 3.6%. In the short term, we believe ongoing inflationary headwinds and prospects of a slowdown may weigh on the company's prospects. On a positive note, the company was able to pass on the higher raw material and energy costs. In the same line, the current shortages of raw materials like recovered paper are expected to stay on a high level over the next few months with the respective impact on costs. Although in the last couple of years the performance of the Paper Division was not encouraging, the supply side squeeze should keep the division's profitability at an acceptable level. Moreover, the operating results of the Packaging and Chemistry divisions are expected to improve. A better bottom-line at Group level along with net sales increases and the cost optimisation efforts are expected to offer a required boost to the company's stock price.

CPH

3

Switzerland | Industrial Goods & Services

Exhibit 1: CPH - Comparison with division peers

Company

EV/EBITDA

P/S

P/E

3 year

3 year

3 year

average

CY2022E

CY2023E

average

CY2022E

CY2023E

average

CY2022E

CY2023E

CPH Chemie & Paper

6.1x

4.5x

5.9x

0.8x

0.6x

0.7x

10.5x

5.8x

9.7x

Paper peers:

Holmen

19.4x

11.6x

14.9x

3.4x

3.3x

3.5x

18.7x

17.5x

24.6x

Stora Enso

10.1x

6.2x

7.2x

1.2x

1.1x

1.1x

13.5x

9.5x

11.5x

Altri

9.9x

6.4x

9.0x

1.2x

1.4x

1.6x

13.3x

7.5x

11.7x

Metsa Board

9.8x

5.3x

6.3x

1.4x

1.2x

1.3x

14.5x

8.0x

10.0x

UPM-Kymmene

9.7x

8.9x

8.0x

1.7x

1.4x

1.4x

17.5x

13.5x

12.5x

Norkse Scogindustrier

4.4x

2.8x

4.3x

0.3x

0.5x

0.4x

24.5x

2.9x

8.2x

James Cropper

16.9x

0.1x

0.1x

1.2x

0.0x

0.0x

42.4x

17.3x

12.5x

OJI Holdings

7.4x

6.5x

6,1

0.4x

0.3x

0.3x

10.8x

7.3x

6.7x

Chemistry peers:

Honeywell Int.

15.7x

15.2x

14.0x

3.8x

3.5x

3.3x

25.1x

21.1x

18.9x

Clariant

12.3x

8.8x

8.6x

1.5x

1..5

1.4x

44.3x

15.3x

15.1x

Arkema

6.4x

5.2x

5.9x

0.9x

0.7x

0.7x

14.1x

8.1x

9.2x

Packaging peers:

MacFarlane Group

8.4x

0.1x

0.1x

0.7x

0.0x

0.0x

16.2x

10.6x

10.4x

Gerresheimer

11.9x

8.8x

7.8x

1.8x

1.2x

1.1x

22.7x

13.2x

11.1x

West Pharmaceutical Services

36.0x

20.9x

18.8x

9.2x

6.9x

6.4x

56.9x

30.5x

27.7x

Convertidora Industrial

3.5x

NA

NA

0.2x

NA

NA

5.9x

NA

NA

PSB Industries

4.1x

NA

NA

0.3x

NA

NA

13.2x

NA

NA

Bilcare Ltd

48.4x

NA

NA

0.1x

NA

NA

16.3x

NA

NA

Median

9.9x

6.5x

7.8x

1.2x

1.2x

1.2x

16.3x

11.9x

11.6x

High

48.4x

20.9x

18.8x

9.2x

6.9x

6.4x

56.9x

30.5x

27.7x

Low

3.5x

0.1x

0.1x

0.1x

0.0x

0.0x

5.9x

2.9x

6.7x

Premium (disc) to peers

(39%)

(31%)

(24%)

(28%)

(46%)

(43%)

(36%)

(51%)

(16%)

Source: Bloomberg and Thomson Eikon (as on 25 July 2022)

Exhibit 2: CPH - Comparison with weighted average of division peers

		EV/EBITDA			P/S			P/E
	3 year			3 year			3 year
	average	CY2022E CY2023E	average CY2022E	CY2023E	average	CY2022E	CY2023E
Weighted peer multiples	13.8x	7.6x	8.1x	1.7x	1.7x	1.6x	21.8x	13.0x	13.6x
CPH	6.1x	4.5x	5.9x	0.8x	0.6x	0.7x	10.5x	5.8x	9.7x
Premium (disc) to peers	(56%)	(42%)	(27%)	(51%)	(62%)	(58%)	(52%)	(55%)	(28%)

Source: Bloomberg and Thomson Eikon (as on 25 July 2022)

CPH 4

Switzerland | Industrial Goods & Services

DETAILED FINANCIAL STATEMENTS

Income Statement

	CHF mn (except per share)		FY17			FY18		FY19		FY20		FY21			FY22E		FY23E
	Chemistry sales	75		79	78		73		95		113	115
	Paper sales		264			301		293		210		231			374		320
	Packaging sales	130		153	153		162		171		220	210
	Net Sales		470			534		525		445		497			707		645
	Cost of Sales	(309)	(311)	(298)	(255)	(336)	(442)	(403)
	Gross profit		161			222		227		190		161			265		243
	Personnel cost	(84)	(92)	(93)	(93)	(92)	(101)	(105)
	Outsourced maintenance/repairs		(17)			(19)		(20)		(17)		(18)			(25)		(26)
	Other operating expense	(26)	(28)	(26)	(25)	(25)	(35)	(35)
	Total operating costs		(127)			(139)		(139)		(135)		(135)			(162)		(166)
	EBITDA	34		83	88		55		26		104	77
	Depreciation		(30)			(30)		(30)		(29)		(27)			(18)		(20)
	Amortisation	(1)		(1)	(1)		(1)		(1)		(1)	(1)
	Operating profit (EBIT)		3			52		57		25		(3)			84		55
	before impairment
	Impairment	0		0	0		0		(150)	0	0
	Operating profit (EBIT)		3			52		57		25		(153)			84		55
	Finance costs	(8)		(7)	(6)		(5)		(5)		(2)	(2)
	Finance income		2			1		0		0		1			0		0
	Total financial income	(7)		(6)	(6)		(5)		(4)		(2)	(2)
	(expenses)
	Profit before taxes (before		(4)			46		51		20		(157)			82		53
	exceptional items)
	Non-operating items	23		0	1		19		7		0	0
	Income taxes		(3)			(3)		(3)		8		(2)			(5)		(8)
	Profit attributable to the	16		42	48		47		(152)		76	45
	parent
	Basic EPS		2.7			7.1		8.1		7.8		(25.3)			12.7		7.5
	Diluted EPS	2.7		7.1	8.1		7.8		(25.3)		12.7	7.5
	DPS		0.7			1.8		1.8		1.8		1.3			1.3		1.8
Source: Research Dynamics, Company data

Balance Sheet

CHF mn	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
Assets
Non-current assets
PPE	384.1	376.1	366.4	352.6	196.5	228.5	235.9
Intangible assets	4.8	5.8	5.6	5.6	5.8	6.0	6.1
Long-term financial assets	10.0	10.0	10.0	10.0	10.0	10.0	10.0
Long-term financial receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other non-current assets	56.4	55.3	54.0	64.8	58.4	58.4	58.4
Total non-current assets	455.3	447.2	436.0	432.9	270.7	302.8	310.4
Current assets
Inventories	59.2	69.6	78.5	78.3	87.5	102.1	95.8
Trade accounts receivable	77.8	72.1	72.4	52.9	69.3	75.6	70.7
Other receivables	18.0	13.1	14.0	17.2	28.5	28.5	28.5
Prepaid expenses and accrued
income	7.0	9.2	8.6	6.7	9.2	9.2	9.2
Short-term financial receivables	0.0	100.3	0.0	0.0	0.1	0.1	0.1
Liquid funds and Securities	80.2	89.0	93.1	116.3	95.1	131.4	149.9
Total assets	697.6	800.5	702.7	704.2	560.4	649.7	664.6
Shareholders' Equity and Liabilities
Share capital	30.0	12.0	12.0	1.2	1.2	1.2	1.2
Capital reserves	0.8	15.0	4.2	4.2	(0.1)	(0.1)	(0.1)
Profit reserves	346.4	336.2	375.2	418.5	459.5	300.2	365.8
Net result for the year	16.0	42.3	48.3	46.9	(151.6)	76.4	45.0
Non-current liabilities
Long-term financial liabilities	143.5	120.5	116.8	109.7	106.6	102.7	98.8
Pension scheme liabilities	0.6	1.3	0.7	1.2	1.4	1.4	1.4
Other long-term liabilities	0.0	0.8	0.6	0.4	0.3	0.3	0.3
Long-term provisions	51.8	50.0	47.5	31.5	24.1	24.1	24.1
Current liabilities
Trade accounts payable	69.5	69.7	66.3	56.8	84.8	109.3	93.9
Other payables	3.3	4.1	3.6	4.6	3.9	3.9	3.9
Accrued liabilities and deferred
income	17.2	20.0	16.3	16.8	18.3	18.3	18.3
Short-term financial liabilities	9.8	125.8	5.9	8.1	3.2	3.1	3.0
Short-term provisions	5.6	1.2	3.8	3.3	7.4	7.4	7.4
Total liabilities	301.3	393.3	261.4	232.4	249.9	270.4	251.0
Total equity and liab.	697.6	800.5	702.7	704.2	560.4	649.7	664.6

Source: Research Dynamics, Company data